| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
34,915 |
30,130 |
$2.10M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,637 |
7,206 |
$671K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,314 |
3,242 |
$281K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,566 |
3,486 |
$276K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,464 |
2,413 |
$193K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,544 |
2,335 |
$189K |
| 87428 |
|
2,961 |
2,843 |
$105K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,376 |
2,272 |
$81K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
879 |
796 |
$70K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,924 |
2,828 |
$40K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,613 |
2,477 |
$35K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,138 |
1,207 |
$34K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
380 |
361 |
$29K |
| 85018 |
|
11,025 |
10,774 |
$26K |
| 99173 |
|
7,837 |
7,653 |
$18K |
| 81000 |
|
5,491 |
5,357 |
$17K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
465 |
454 |
$16K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
296 |
287 |
$10K |
| 83655 |
|
788 |
768 |
$9K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
106 |
103 |
$9K |
| 99199 |
Unlisted special service, procedure or report |
1,562 |
1,540 |
$5K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
751 |
732 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
97 |
93 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
335 |
316 |
$4K |
| 99383 |
|
45 |
45 |
$4K |
| 90734 |
|
109 |
106 |
$4K |
| 90670 |
|
255 |
249 |
$4K |
| 3008F |
|
139 |
137 |
$3K |
| 99051 |
|
2,896 |
2,770 |
$3K |
| 90686 |
|
269 |
266 |
$3K |
| 86756 |
|
356 |
337 |
$2K |
| 81003 |
|
964 |
916 |
$2K |
| 90648 |
|
174 |
171 |
$2K |
| 36416 |
|
9,369 |
9,169 |
$2K |
| 90723 |
|
150 |
146 |
$2K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
16 |
15 |
$2K |
| 90633 |
|
139 |
137 |
$2K |
| 99384 |
|
13 |
12 |
$1K |
| 90680 |
|
89 |
88 |
$957.00 |
| 1038F |
|
48 |
39 |
$950.00 |
| 90651 |
|
35 |
31 |
$914.09 |
| 86308 |
|
158 |
154 |
$805.47 |
| 96127 |
|
130 |
125 |
$633.94 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,643 |
1,590 |
$588.34 |
| 90710 |
|
16 |
16 |
$570.78 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
50 |
49 |
$412.91 |
| 1000F |
|
14 |
14 |
$350.00 |
| 3016F |
|
14 |
14 |
$350.00 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
89 |
87 |
$346.93 |
| 1036F |
|
13 |
13 |
$325.00 |
| 81025 |
|
41 |
39 |
$289.63 |
| 90647 |
|
19 |
18 |
$187.00 |
| 90461 |
|
13 |
13 |
$11.55 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
27 |
26 |
$7.21 |